{
    "organizations": [],
    "uuid": "568024957e462f2c5b91ccef5646bf80b3918f79",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/idUSL8N1PX3GC",
    "ord_in_thread": 0,
    "title": "BRIEF-Bionaturis Gets Patent For BNT005 In US",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - BIOORGANIC RESEARCH AND SERVICES SA (BIONATURIS):\n* SAYS GETS PATENT IN UNITED STATES FOR ITS MOLECULE USEFUL IN IMMUNOTHERAPY FOR CANINE LEISHMANIASIS\n* SAYS GETS 196,300 EURO GRANT TO DEVELOP THE PROJECT, TO APPLY FOR MARKETING AUTHORIZATION OF BNT005 IN ARGENTINA\nSource text: bit.ly/2sfrcCb\nFurther company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-07T18:31:00.000+02:00",
    "crawled": "2018-02-09T05:43:19.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "bioorganic",
        "research",
        "service",
        "sa",
        "bionaturis",
        "say",
        "get",
        "patent",
        "united",
        "state",
        "molecule",
        "useful",
        "immunotherapy",
        "canine",
        "leishmaniasis",
        "say",
        "get",
        "euro",
        "grant",
        "develop",
        "project",
        "apply",
        "marketing",
        "authorization",
        "bnt005",
        "argentina",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}